Chembio Receives First Order from PEPFAR's Supply Chain Management System

Chembio Receives First Order from PEPFAR's Supply Chain Management System

Business Wire - August 3, 2006

MEDFORD, N.Y. -- Chembio Diagnostics, Inc. (OTCBB:CEMI) has received its first order from the new Supply Chain Management System (SCMS) established recently under the auspices of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). The order is for 50,000 HIV 1/2 STAT-PAK(TM) tests to be used in connection with the ongoing scale-up of rapid testing in Nigeria. This ramp up in testing will be necessary in order for the country, one of the fifteen original PEPFAR focus countries, to meet its HIV treatment targets under PEPFAR and other programs.

SCMS is designed to improve the supply chain that delivers an uninterrupted supply of high-quality, affordable products abroad. The project will focus on better forecasting to determine what products are needed, as well as aggregating demand and improving systems for storage, transport and distribution. The SCMS supply chain will be transparent, accountable and tailored to specific country needs. The SCMS project team is led by the Partnership for Supply Chain Management (PSCM), a nonprofit organization established by JSI Research & Training Institute (JSI) and Management Sciences for Health (MSH). The project team includes 17 institutions including large multinationals Northrop Grumman Information Technology and UPS Supply Chain Solutions.

Chembio believes it is extremely well positioned to participate in ongoing procurements from SCMS as a result of its competitively priced, FDA-approved products that are manufactured in the United States. Further information on SCMS can be viewed at http://portalprd1.jsi.com/portal/page?_pageid=273,4810405,273_4810524& _dad=portal&_schema=PORTAL (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

ABOUT CHEMBIO

Chembio Diagnostics, Inc., a developer and manufacturer of rapid diagnostic tests for infectious diseases, is on the frontlines of the global battle against the AIDS pandemic. The Company has received marketing approval from the FDA for its SURE CHECK(R) HIV 1/2 and HIV 1/2 STAT-PAK(TM) rapid tests. The Company also manufactures rapid tests for veterinary Tuberculosis and Chagas Disease, and has developed a patent-pending technology, the Dual Path Platform (DPP(TM)), for its next generation HIV and other rapid tests. For additional information please visit www.chembio.com.

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed the audit of those results. Actual revenue may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing, to obtain regulatory approvals in a timely manner, and the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

CONTACT: The Investor Relations Group

Investors:

James Carbonara / Andrea Raetzer, 212-825-3210

Media:

Susan Morgenbesser, 212-825-3210

SOURCE: Chembio Diagnostics, Inc.
060803
BW060807

Copyright © 2006 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .